Single linker FabFv antibodies and methods of producing same

ABSTRACT

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

This application is a continuation of U.S. patent application Ser. No. 14/654,240, filed Jun. 19, 2015, which is a U.S. National Phase application under 35 U.S.C. § 371 of PCT/EP2013/077758, filed Dec. 20, 2013, which claims priority from and the benefit of United Kingdom Application No.: 1223276.5, filed on Dec. 21, 2012, the specifications of which are hereby incorporated by reference in their entireties.

The present disclosure relates to certain multi-specific constructs, pharmaceutical formulations comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure also extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

WO2009/040562 and WO2010/035012 discloses certain bi-specific molecules useful as therapeutic agents, known as Fab-Fv or Fab-dsFv respectively. The molecules of this type have good binding affinity for the antigens to which they are specific and no significant occlusion of antigen binding sites occurs in the format. Whilst a high percentage of these antibody molecules are expressed as functional monomer there is a proportion that aggregates and from which the monomer needs to be purified.

The present inventors have re-engineered the molecules concerned to provide molecules with equivalent functionality, whilst minimising aggregation at the expression stage and thus substantially increasing the yield of monomer.

In one embodiment there is provided a multi-specific antibody molecule comprising or consisting of three polypeptides:

a) a polypeptide chain of formula (I): (Vxx)_(n)Vx-Cx-X-V₁; and b) a polypeptide chain of formula (II): (Vyy)_(n)Vy-C_(y) c) a polypeptide of formula (III): V₂ wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region domain, X represents a linker, V₁ represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region domain, V₂ represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) are aligned such that the constant regions Cx and Cy are paired and the variable domain Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V₁ and V₂, in particular where a disulphide bond is present.

In one embodiment Vxx and Vyy are also paired to form a binding domain.

In one embodiment a disulphide bond is present between V₁ and V₂.

In one embodiment there is provided a bi-specific antibody molecule comprising or consisting of three polypeptides;

a) a heavy chain of formula (Ia): VH—CH₁—X—V₁; and b) a light chain of formula (IIa): VL-C_(L) c) a polypeptide of formula (III): V₂ wherein VH represents a heavy chain variable domain, CH₁ represents domain 1 of a heavy chain constant region, X represents a linker, V₁ represents a variable domain, V_(L) represents a light chain variable domain, C_(L) represents a constant region from a light chain, V₂ represents a variable domain, wherein optionally a disulphide bond is present between V₁ and V₂, in particular where a disulphide bond is present.

In one embodiment there is provided a bi-specific antibody molecule comprising or consisting of three polypeptides;

a) a heavy chain of formula (Ib): VH-CH₁; and b) a light chain of formula (IIb): VL-C_(L)-X—V₂ c) a polypeptide of formula (III): V₁ wherein VH represents a heavy chain variable domain, CH₁ represents domain 1 of a heavy chain constant region, X represents a linker, V₁ represents a variable domain, V_(L) represents a light chain variable domain, C_(L) represents a constant region from a light chain, V₂ represents a variable domain, wherein optionally a disulphide bond is present between V₁ and V₂, in particular where a disulphide bond is present.

In one embodiment a disulphide bond is present between V₁ and V₂.

Advantageously, the present construct minimises the amount of aggregation seen during expression and maximises the amount of monomer obtained, for example the monomer may be 50%, 60%, 70% or 75% or more such as 80 or 90% or more of the protein expressed.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows various sequences for single linker Fab-Fv constructs according to the invention and comparator constructs Fabdsscfv and FabdsFv. (1A) A26Fab-645dsFv sequences, (1B) Single linker A26Fab-645dsFv (LC-vL linked) sequences, (1C) Single linker A26Fab-645dsFv (HC-vH linked) sequences, (1D) A26Fab-645dsscFv (HC-scFv) sequences, (1E) A26Fab-645dsscFv (LC-scFv) sequences, (1F) Fab, Fab-648g and 648g sequences, (1G) 645 CDR, 648 CDR and anti-albumin antibody sequences

FIG. 2 shows SDS-PAGE analysis of the various constructs

FIG. 3 shows size exclusion analysis of various constructs

FIG. 4 shows a diagrammatic representation of various example constructs according to the disclosure

FIG. 5 shows transient expression of single linker Fab-dsFvs expressed from triple gene plasmids in CHO cells.

FIG. 6 shows SDS-PAGE analysis of various single linker Fab-dsFvs expressed from triple gene plasmids.

FIG. 7 shows size exclusion analysis of single linker Fab-dsFv expressed from a triple gene plasmids.

DETAILED DESCRIPTION OF THE INVENTION

Multi-specific antibody as employed herein refers to an antibody molecule as described herein which has two or more binding domains, for example two or three binding domains. In one embodiment the construct is a tri-specific antibody. Tri-specific molecule as employed herein refers to a molecule with three antigen binding sites, which may independently bind the same or different antigens.

In one embodiment the construct is a bi-specific antibody. Bi-specific molecule as employed herein refers to a molecule with two antigen binding sites, which may bind the same or different antigens.

In one embodiment the domains all bind the same antigen, including binding the same epitope on the antigen or binding different epitopes on the antigen.

In one embodiment there are three binding domains and each of the three binding domains bind different (distinct) antigens.

In one embodiment there are three binding domains and two binding domains bind the same antigen, including binding the same epitope or different epitopes on the same antigen, and the third binding domain binds a different (distinct) antigen.

In one embodiment the present disclosure relates to a bi-specific antibody comprising or consisting of three polypeptide chains.

The multi-specific molecules according to the present disclosure are provided as a dimer of a heavy and light chain of:

-   -   formula (I) and (II) respectively, wherein the Vx-Cx portion         together with the Vy-Cy portion form a functional Fab or Fab′         fragment, or alternatively     -   formula (Ia) and (IIa), wherein the VH-CH₁ portion together with         the VL-C_(L) form a functional Fab or Fab′ fragment.

In one embodiment the construct of the present disclosure has only two antigen binding sites.

Antigen binding site as employed herein refers to a portion of the molecule, which comprises a pair of variable regions, in particular a cognate pair, that interact specifically with the target antigen.

Specifically as employed herein is intended to refer to a binding site that only recognises the antigen to which it is specific or a binding site that has significantly higher binding affinity to the antigen to which is specific compared to affinity to antigens to which it is non-specific, for example 5, 6, 7, 8, 9, 10 times higher binding affinity.

Binding affinity may be measured by standard assay, for example surface plasmon resonance, such as BIAcore™.

In one embodiment one or more natural or engineered inter chain (i.e. inter light and heavy chain) disulphide bonds are present in the functional Fab or Fab′ fragment.

In one embodiment a “natural” disulfide bond is present between a CH₁ and C_(L) or corresponding components Cx and Cy in the polypeptide chains of formula (I) and (II). Below references to CH₁ may apply equally to Cx. Below references to C_(L) may apply equally to Cy.

When the C_(L) domain is derived from either Kappa or Lambda the natural position for a bond forming cysteine is 214 in human cKappa and cLambda (Kabat numbering 4^(th) edition 1987).

The exact location of the disulfide bond forming cysteine in CH₁ depends on the particular domain actually employed. Thus, for example in human gamma-1 the natural position of the disulfide bond is located at position 233 (Kabat numbering 4^(th) edition 1987). The position of the bond forming cysteine for other human isotypes such as gamma 2, 3, 4, IgM and IgD are known, for example position 127 for human IgM, IgE, IgG2, IgG3, IgG4 and 128 of the heavy chain of human IgD and IgA2B.

A disulfide bond or bond(s) in the constant region of the molecule may be in addition to the optional disulfide bond between a variable domain pair V₁ and V₂.

In one embodiment the multi-specific antibody according to the disclosure has a disulfide bond in a position equivalent or corresponding to that in the naturally occurring between CH₁ and C_(L).

In one embodiment a constant region comprising CH₁ and a constant region such as C_(L) has a disulfide bond which is in a non-naturally occurring position. This may be engineered into the molecule by introducing cysteine(s) into the amino acid chain at the position or positions required. This non-natural disulfide bond is in addition to or as an alternative to the natural disulfide bond present between CH₁ and C_(L).

Introduction of engineered cysteines can be performed using any method known in the art. These methods include, but are not limited to, PCR extension overlap mutagenesis, site-directed mutagenesis or cassette mutagenesis (see, generally, Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N Y, 1989; Ausbel et al., Current Protocols in Molecular Biology, Greene Publishing & Wiley-Interscience, N Y, 1993). Site-directed mutagenesis kits are commercially available, e.g. QuikChange® Site-Directed Mutagenesis kit (Stratagene, La Jolla, Calif.). Cassette mutagenesis can be performed based on Wells et al., 1985, Gene, 34:315-323. Alternatively, mutants can be made by total gene synthesis by annealing, ligation and PCR amplification and cloning of overlapping oligonucleotides.

In one embodiment a disulfide bond between CH₁ and C_(L) is completely absent, for example the interchain cysteines may be replaced by another amino acid, such as serine. Thus there are no inter chain disulphide bonds in the functional Fab fragment of the molecule. Disclosures such as WO2005/003170, incorporated herein by reference, describe how to provide Fab fragments without an inter chain disulphide bond.

In one embodiment n is 1 in the polypeptide chain of formula (I).

In one embodiment n is 1 in the polypeptide chain of formula (II).

In one embodiment n is 1 in the polypeptide chain of formula (I) and (II).

In one embodiment n is 0 in the polypeptide chain of formula (I) and (II).

Vxx may be derived from a heavy chain variable region, light chain variable region or a combination thereof and may comprise an amino acid linker of 1 to 20 amino acids, for example as described below. In one embodiment Vxx consists of a variable region, in particular a variable region derived from a heavy chain. In one embodiment Vxx represents a light chain variable domain. In one embodiment Vxx is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment Vxx is humanised.

Vx may be derived from a heavy chain variable region, light chain variable region or a combination thereof, in particular a variable region derived from a heavy chain. In one embodiment Vx represents a light chain variable domain. In one embodiment Vx is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment Vx is humanised.

Vx in polypeptides of formula (I) corresponds to VH in polypeptide chain (Ia).

VH represents a variable domain, for example a heavy chain variable domain. In one embodiment VH represents a heavy chain variable domain. In one embodiment V_(H) is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment VH is humanised.

V₁ represents a variable domain, for example a heavy chain or light chain variable domain. In one embodiment V₁ represents a heavy chain variable domain. In one embodiment V₁ represents a light chain variable domain. In one embodiment V₁ is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment V₁ is humanised.

Vyy may be derived from a heavy chain, light chain or a combination thereof and may comprise an amino acid linker of 1 to 20 amino acids, for example as described below. In one embodiment Vyy consists of a variable region, in particular a variable region derived from a light chain. In one embodiment Vyy represents a heavy chain variable domain. In one embodiment Vyy is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment Vyy is humanised.

Vy may be derived from a heavy chain variable region, light chain variable region or a combination thereof, in particular a variable region derived from a light chain. In one embodiment Vy represents a heavy chain variable domain. In one embodiment Vy is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment Vy is humanised.

Vy in polypeptides of formula (II) corresponds to VL in polypeptides of formula (IIa).

V_(L) represents a variable domain, for example a light chain variable domain. In one embodiment V_(L) represents a light chain variable domain. In one embodiment VL is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment V_(L) is humanised.

V₂ represents a variable domain, for example a heavy chain or light chain variable domain. In one embodiment V₂ represents a light chain variable domain. In one embodiment V₂ represents a heavy chain variable domain. In one embodiment V₂ is a chimeric variable domain, that is to say it comprises components derived from at least two species, for example a human framework and non-human CDRs. In one embodiment V₁ is humanised.

Generally Vxx and Vyy together form an antigen binding domain. In one embodiment Vxx and Vyy together represent a cognate pair.

Generally Vx and Vy together form an antigen binding domain. In one embodiment Vx and Vy together represent a cognate pair.

In one embodiment the binding domain formed by VH and VL are specific to a first antigen.

In one embodiment VH and VL form a cognate pair.

Generally V₁ and V₂ together form an antigen binding domain. In one embodiment V₁ and V₂ together represent a cognate pair.

In one embodiment V₁ and V₂ together form an antigen binding domain specific for a first antigen (i.e. the two binding domains in the molecule may be specific to the same antigen, for example binding the same or a different epitope therein).

In one embodiment V₁ and V₂ together are a binding domain for human serum albumin.

In one embodiment V₁ and V₂ together form an antigen binding domain specific for a second antigen (i.e. the two binding domains in the molecule are specific to different antigens).

In one embodiment the disulfide bond between V₁ and V₂ is between two of the residues listed below (unless the context indicates otherwise Kabat numbering is employed in the list below). Wherever reference is made to Kabat numbering the relevant reference is Kabat et al., 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA. In one embodiment the disulfide bond is in a position selected from the group comprising:

-   -   VH37+VL95C see for example Protein Science 6, 781-788 Zhu et al         (1997);     -   VH44+VL100 see for example; Biochemistry 33 5451-5459 Reiter et         al (1994); or Journal of Biological Chemistry Vol. 269 No. 28         pp. 18327-18331 Reiter et al (1994); or Protein Engineering,         vol. 10 no. 12 pp. 1453-1459 Rajagopal et al (1997);     -   VH44+VL105 see for example J Biochem. 118, 825-831 Luo et al         (1995);     -   VH45+VL87 see for example Protein Science 6, 781-788 Zhu et al         (1997);     -   VH55+VL101 see for example FEBS Letters 377 135-139 Young et al         (1995);     -   VH100+VL50 see for example Biochemistry 29 1362-1367 Glockshuber         et al (1990);     -   VH100b+VL49;     -   VH98+VL46 see for example Protein Science 6, 781-788 Zhu et al         (1997);     -   VH101+VL46;     -   VH105+VL43 see for example; Proc. Natl. Acad. Sci. USA Vol. 90         pp. 7538-7542 Brinkmann et al (1993); or Proteins 19, 35-47 Jung         et al (1994),     -   VH106+VL57 see for example FEBS Letters 377 135-139 Young et         al (1995) and a position corresponding thereto in variable         region pair located in the molecule.

The amino acid pairs listed above are in the positions conducive to replacement by cysteines such that disulfide bonds can be formed. Cysteines can be engineered into these desired positions by known techniques. In one embodiment therefore an engineered cysteine according to the present invention refers to where the naturally occurring residue at a given amino acid position has been replaced with a cysteine residue.

Introduction of engineered cysteines can be performed using any method known in the art. These methods include, but are not limited to, PCR extension overlap mutagenesis, site-directed mutagenesis or cassette mutagenesis (see, generally, Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N Y, 1989; Ausbel et al., Current Protocols in Molecular Biology, Greene Publishing & Wiley-Interscience, N Y, 1993). Site-directed mutagenesis kits are commercially available, e.g. QuikChange® Site-Directed Mutagenesis kit (Stratagen, La. Jolla, Calif.). Cassette mutagenesis can be performed based on Wells et al., 1985, Gene, 34:315-323. Alternatively, mutants can be made by total gene synthesis by annealing, ligation and PCR amplification and cloning of overlapping oligonucleotides.

Accordingly in one embodiment a variable domain pair (V₁/V₂) of the present invention may be linked by a disulfide bond between two cysteine residues, one in V₁ and one in V₂, wherein the position of the pair of cysteine residues is selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH100b and VL49, VH98 and VL46, VH101 and VL46, VH105 and VL43 and VH106 and VL57.

In one embodiment a variable domain pair (V₁/V₂) of the present invention may be linked by a disulfide bond between two cysteine residues, one in V₁ and one in V₂, which are outside of the CDRs wherein the position of the pair of cysteine residues is selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH98 and VL46, VH105 and VL43 and VH106 and VL57.

In one embodiment V₁ is a heavy chain variable domain and V₂ is a light chain variable domain and V₁ and V₂ are linked by a disulphide bond between two engineered cysteine residues, one at position VH44 of V₁ and the other at VL100 of V₂.

In one embodiment VH and V₁ are variable regions which are both from a heavy chain(s) or a light chain(s), in particular are both derived from two distinct heavy chain variable regions.

In one embodiment VL and V₂ are variable regions which are both from a heavy chain(s) or a light chain(s), in particular are both derived from two distinct light chain variable regions.

Cognate pair as employed herein refers to a pair of variable domains from a single antibody, which was generated in vivo, i.e. the naturally occurring pairing of the variable domains isolated from a host. A cognate pair is therefore a VH and VL pair. In one example the cognate pair bind the antigen co-operatively.

Variable region as employed herein refers to the region in an antibody chain comprising the CDRs and a suitable framework.

Variable regions for use in the present disclosure will generally be derived from an antibody, which may be generated by any method known in the art.

Derived from as employed herein refers to the fact that the sequence employed or a sequence highly similar to the sequence employed was obtained from the original genetic material, such as the light or heavy chain of an antibody.

Highly similar as employed herein is intended to refer to an amino acid sequence which over its full length is 95% similar or more, such as 96, 97, 98 or 99% similar.

Antibodies generated against the antigen polypeptide may be obtained, where immunisation of an animal is necessary, by administering the polypeptides to an animal, preferably a non-human animal, using well-known and routine protocols, see for example Handbook of Experimental Immunology, D. M. Weir (ed.), Vol 4, Blackwell Scientific Publishers, Oxford, England, 1986). Many warm-blooded animals, such as rabbits, mice, rats, sheep, cows, camels or pigs may be immunized. However, mice, rabbits, pigs and rats are generally most suitable.

Monoclonal antibodies may be prepared by any method known in the art such as the hybridoma technique (Kohler & Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today, 4:72) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, pp 77-96, Alan R Liss, Inc., 1985).

Antibodies may also be generated using single lymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNAs generated from single lymphocytes selected for the production of specific antibodies by, for example, the methods described by Babcook, J. et al., 1996, Proc. Natl. Acad. Sci. USA 93(15):7843-78481; WO92/02551; WO2004/051268 and WO2004/106377.

The antibodies for use in the present invention can also be generated using various phage display methods known in the art and include those disclosed by Brinkman et al. (in J. Immunol. Methods, 1995, 182: 41-50), Ames et al. (J. Immunol. Methods, 1995, 184:177-186), Kettleborough et al. (Eur. J. Immunol. 1994, 24:952-958), Persic et al. (Gene, 1997 187 9-18), Burton et al. (Advances in Immunology, 1994, 57:191-280) and WO90/02809; WO91/10737; WO92/01047; WO92/18619; WO93/11236; WO95/15982; WO95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743; 5,969,108, and WO20011/30305.

In one embodiment the bi-specific molecules according to the disclosure are humanised.

Humanised (which include CDR-grafted antibodies) as employed herein refers to molecules having one or more complementarity determining regions (CDRs) from a non-human species and a framework region from a human immunoglobulin molecule (see, e.g. U.S. Pat. No. 5,585,089; WO91/09967). It will be appreciated that it may only be necessary to transfer the specificity determining residues of the CDRs rather than the entire CDR (see for example, Kashmiri et al., 2005, Methods, 36, 25-34). Humanised antibodies may optionally further comprise one or more framework residues derived from the non-human species from which the CDRs were derived.

As used herein, the term ‘humanised antibody molecule’ refers to an antibody molecule wherein the heavy and/or light chain contains one or more CDRs (including, if desired, one or more modified CDRs) from a donor antibody (e.g. a murine monoclonal antibody) grafted into a heavy and/or light chain variable region framework of an acceptor antibody (e.g. a human antibody). For a review, see Vaughan et al, Nature Biotechnology, 16, 535-539, 1998. In one embodiment rather than the entire CDR being transferred, only one or more of the specificity determining residues from any one of the CDRs described herein above are transferred to the human antibody framework (see for example, Kashmiri et al., 2005, Methods, 36, 25-34). In one embodiment only the specificity determining residues from one or more of the CDRs described herein above are transferred to the human antibody framework. In another embodiment only the specificity determining residues from each of the CDRs described herein above are transferred to the human antibody framework.

When the CDRs or specificity determining residues are grafted, any appropriate acceptor variable region framework sequence may be used having regard to the class/type of the donor antibody from which the CDRs are derived, including mouse, primate and human framework regions. Suitably, the humanised antibody according to the present invention has a variable domain comprising human acceptor framework regions as well as one or more of the CDRs provided herein.

Examples of human frameworks which can be used in the present invention are KOL, NEWM, REI, EU, TUR, TEI, LAY and POM (Kabat et al., supra). For example, KOL and NEWM can be used for the heavy chain, REI can be used for the light chain and EU, LAY and POM can be used for both the heavy chain and the light chain. Alternatively, human germline sequences may be used; these are available at: http://vbase.mrc-cpe.cam.ac.uk/

In a humanised antibody of the present invention, the acceptor heavy and light chains do not necessarily need to be derived from the same antibody and may, if desired, comprise composite chains having framework regions derived from different chains.

The framework regions need not have exactly the same sequence as those of the acceptor antibody. For instance, unusual residues may be changed to more frequently-occurring residues for that acceptor chain class or type. Alternatively, selected residues in the acceptor framework regions may be changed so that they correspond to the residue found at the same position in the donor antibody (see Reichmann et al., 1998, Nature, 332, 323-324). Such changes should be kept to the minimum necessary to recover the affinity of the donor antibody. A protocol for selecting residues in the acceptor framework regions which may need to be changed is set forth in WO91/09967.

In one embodiment the bi-specific antibodies of the present disclosure are fully human, in particular one or more of the variable domains are fully human.

Fully human molecules are those in which the variable regions and the constant regions (where present) of both the heavy and the light chains are all of human origin, or substantially identical to sequences of human origin, not necessarily from the same antibody. Examples of fully human antibodies may include antibodies produced, for example by the phage display methods described above and antibodies produced by mice in which the murine immunoglobulin variable and optionally the constant region genes have been replaced by their human counterparts eg. as described in general terms in EP0546073 B1, U.S. Pat. Nos. 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, EP 0438474 and EP0463151.

Cx is a constant domain from a light or heavy chain, in particular a heavy chain.

Cx in polypeptide of formula (I) corresponds to CH₁ in polypeptides of formula (Ia). In one embodiment Cx is equivalent to CH₁.

In one embodiment the CH₁ domain is a naturally occurring domain 1 from a heavy chain or a derivative thereof. In one embodiment the CH fragment consists of a CH₁ domain.

Cy is a constant domain from a light or heavy chain, in particular a light chain.

Cy in polypeptide of formula (II) corresponds to CL in polypeptides of formula (IIa). In one embodiment Cy is equivalent to CL.

In one embodiment the C_(L) fragment, in the light chain, is a constant kappa sequence or a constant lambda sequence or a derivative thereof.

A derivative of a naturally occurring domain as employed herein is intended to refer to where one, two, three, four or five amino acids in a naturally occurring sequence have been replaced or deleted, for example to optimize the properties of the domain such as by eliminating undesirable properties but wherein the characterizing feature(s) of the domain is/are retained.

In one embodiment X is a linker for example a suitable peptide for connecting the portions CH₁ and V₁.

In one embodiment X is a linker for example a suitable peptide for connecting the portions C_(L) and V₂.

In one embodiment the peptide linker is 50 amino acids in length or less, for example 20 amino acids or less.

In one embodiment the linker is selected from a sequence shown in sequence 13 to 77.

In one embodiment the linker is selected from a sequence shown in SEQ ID NO: 103 or SEQ ID NO:104.

TABLE 1 Hinge linker sequences SEQ ID NO: SEQUENCE 13 DKTHTCAA 14 DKTHTCPPCPA 15 DKTHTCPPCPATCPPCPA 16 DKTHTCPPCPATCPPCPATCPPCPA 17 DKTHTCPPCPAGKPTLYNSLVMSDTAGTCY 18 DKTHTCPPCPAGKPTHVNVSVVMAEVDGTCY 19 DKTHTCCVECPPCPA 20 DKTHTCPRCPEPKSCDTPPPCPRCPA 21 DKTHTCPSCPA

TABLE 2 Flexible linker sequences SEQ ID NO: SEQUENCE 22 SGGGGSE 23 DKTHTS 24 (S)GGGGS 25 (S)GGGGSGGGGS 26 (S)GGGGSGGGGSGGGGS 27 (S)GGGGSGGGGSGGGGSGGGGS 28 (S)GGGGSGGGGSGGGGSGGGGSGGGGS 29 AAAGSG-GASAS 30 AAAGSG-XGGGS-GASAS 31 AAAGSG-XGGGSXGGGS-GASAS 32 AAAGSG-XGGGSXGGGSXGGGS-GASAS 33 AAAGSG-XGGGSXGGGSXGGGSXGGGS-GASAS 34 AAAGSG-XS-GASAS 35 PGGNRGTTTTRRPATTTGSSPGPTQSHY 36 ATTTGSSPGPT 37 ATTTGS — GS 38 EPSGPISTINSPPSKESHKSP 39 GTVAAPSVFIFPPSD 40 GGGGIAPSMVGGGGS 41 GGGGKVEGAGGGGGS 42 GGGGSMKSHDGGGGS 43 GGGGNLITIVGGGGS 44 GGGGVVPSLPGGGGS 45 GGEKSIPGGGGS 46 RPLSYRPPFPFGFPSVRP 47 YPRSIYIRRRHPSPSLTT 48 TPSHLSHILPSFGLPTFN 49 RPVSPFTFPRLSNSWLPA 50 SPAAHFPRSIPRPGPIRT 51 APGPSAPSHRSLPSRAFG 52 PRNSIHFLHPLLVAPLGA 53 MPSLSGVLQVRYLSPPDL 54 SPQYPSPLTLTLPPHPSL 55 NPSLNPPSYLHRAPSRIS 56 LPWRTSLLPSLPLRRRP 57 PPLFAKGPVGLLSRSFPP 58 VPPAPVVSLRSAHARPPY 59 LRPTPPRVRSYTCCPTP- 60 PNVAHVLPLLTVPWDNLR 61 CNPLLPLCARSPAVRTFP

(S) is optional in sequences 24 to 28.

Examples of rigid linkers include the peptide sequences GAPAPAAPAPA (SEQ ID NO: 62), PPPP (SEQ ID NO: 63) and PPP.

In one embodiment the peptide linker is an albumin binding peptide.

Examples of albumin binding peptides are provided in WO2007/106120 and include:

TABLE 3 SEQ ID NO: SEQUENCE 64 DLCLRDWGCLW 65 DICLPRWGCLW 66 MEDICLPRWGCLWGD 67 QRLMEDICLPRWGCLWEDDE 68 QGLIGDICLPRWGCLWGRSV 69 QGLIGDICLPRWGCLWGRSVK 70 EDICLPRWGCLWEDD 71 RLMEDICLPRWGCLWEDD 72 MEDICLPRWGCLWEDD 73 MEDICLPRWGCLWED 74 RLMEDICLARWGCLWEDD 75 EVRSFCTRWPAEKSCKPLRG 76 RAPESFVCYWETICFERSEQ 77 EMCYFPGICWM

Advantageously use of albumin binding peptides as a linker may increase the half-life of the bi-specific antibody molecule.

For the avoidance of doubt V₂ is still present in the antibody molecule and is retained therein by virtue of pairing with V₁ including where a disulphide bond is present between V₁ and V₂.

In one embodiment the bi-specific antibody molecules of the disclosure are capable of selectively binding two different antigens of interest.

In one embodiment, an antigen of interest bound by Vxx/Vyy, Vx/Vy, VH/VL and V₁/V₂ are independently selected from a cell-associated protein, for example a cell surface protein on cells such as bacterial cells, yeast cells, T-cells, endothelial cells or tumour cells, and a soluble protein.

Antigens of interest may also be any medically relevant protein such as those proteins upregulated during disease or infection, for example receptors and/or their corresponding ligands. Particular examples of cell surface proteins include adhesion molecules, for example integrins such as 11 integrins e.g. VLA-4, E-selectin, P selectin or L-selectin, CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CDW52, CD69, CD134 (OX40), ICOS, BCMP7, CD137, CD27L, CDCP1, DPCR1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, nectin-like2, NKCC1, PTK7, RAIG1, TCAM1, SC6, BCMP101, BCMP84, BCMP11, DTD, carcinoembryonic antigen (CEA), human milk fat globulin (HMFG1 and 2), MHC Class I and MHC Class II antigens, and VEGF, and where appropriate, receptors thereof.

Soluble antigens include interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16 or IL-17, IL-23, viral antigens for example respiratory syncytial virus or cytomegalovirus antigens, immunoglobulins, such as IgE, interferons such as interferon α, interferon β or interferon γ, tumour necrosis factor-α, tumor necrosis factor-β, colony stimulating factors such as G-CSF or GM-CSF, and platelet derived growth factors such as PDGF-α, and PDGF-β and where appropriate receptors thereof. Other antigens include bacterial cell surface antigens, bacterial toxins, viruses such as influenza, EBV, HepA, B and C, bioterrorism agents, radionuclides and heavy metals, and snake and spider venoms and toxins.

In one embodiment, the antibody fusion protein of the invention may be used to functionally alter the activity of the antigen of interest. For example, the antibody fusion protein may neutralize, antagonize or agonise the activity of said antigen, directly or indirectly.

In one embodiment the antigen of interest bound by VH and VL is OX40. In one embodiment the Vx-Cx or VHCH1 portion of the multi-specific antibody has the sequence given in SEQ ID NO:3. In one embodiment the Vy-Cy or VL-CL portion of the multi-specific antibody has the sequence given in SEQ ID NO:7.

In one embodiment, an antigen of interest bound by VH/VL or V₁/V₂ provides the ability to recruit effector functions, such as complement pathway activation and/or effector cell recruitment.

The recruitment of effector function may be direct in that effector function is associated with a cell, said cell bearing a recruitment molecule on its surface. Indirect recruitment may occur when binding of a binding domain (such as V₁/V₂) in the molecule according to present disclosure to a recruitment polypeptide causes release of, for example, a factor which in turn may directly or indirectly recruit effector function, or may be via activation of a signalling pathway. Examples include TNFα, IL2, IL6, IL8, IL17, IFNγ, histamine, C1q, opsonin and other members of the classical and alternative complement activation cascades, such as C2, C4, C3-convertase, and C5 to C9.

As used herein, ‘a recruitment polypeptide’ includes a FcγR such as FcγRI, FcγRII and FcγRIII, a complement pathway protein such as, but without limitation, C1q and C3, a CD marker protein (Cluster of Differentiation marker) such as, but without limitation, CD68, CD115, CD16, CD80, CD83, CD86, CD56, CD64, CD3, CD4, CD8, CD28, CD45, CD19, CD20 and CD22. Further recruitment polypeptides which are CD marker proteins include CD1, CD1d, CD2, CD5, CD8, CD9, CD10, CD11, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD40, CD43, CD44, CD45, CD46, CD49, CD49a, CD49b, CD49c, CD49d, CD52, CD53, CD54, CD55, CD56, CD58, CD59, CD61, CD62, D62E, CD62L, CD62P, CD63, CD64, CD66e, CD68, CD70, CD71, CD72, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD88, CD89, CD90, CD94, CD95, CD98, CD106, CD114, CD116, CD117, CD118, CD120, CD122, CD130, CD131, CD132, CD133, CD134, CD135, CD137, CD138, CD141, CD142, CD143, CD146, CD147, CD151, CD152, CD153, CD154, CD155, CD162, CD164, CD169, CD184, CD206, CD209, CD257, CD278, CD281, CD282, CD283 and CD304, or a fragment of any thereof which retains the ability to recruit cell-mediated effector function either directly or indirectly. A recruitment polypeptide also includes immunoglobulin molecules such as IgG1, IgG2, IgG3, IgG4, IgE and IgA which possess effector function.

In one embodiment, a binding domain (such as V₁/V₂) in the molecule according to the present disclosure has specificity is a complement pathway protein, with C1q being particularly preferred.

Further, molecules of the present invention may be used to chelate radionuclides by virtue of a single domain antibody which binds to a nuclide chelator protein. Such fusion proteins are of use in imaging or radionuclide targeting approaches to therapy.

In one embodiment, one binding domain in a molecule according to the disclosure (such as V₁/V₂) has specificity is a CD marker protein, with CD68, CD80, CD86, CD64, CD3, CD4, CD8 CD45, CD16 and CD35 being particularly preferred.

In one embodiment a binding domain within a molecule according to the disclosure (such as V₁/V₂) has specificity for a serum carrier protein, a circulating immunoglobulin molecule, or CD35/CR1, for example for providing an extended half-life to the antibody fragment with specificity for said antigen of interest by binding to said serum carrier protein, circulating immunoglobulin molecule or CD35/CR1.

As used herein, ‘serum carrier proteins’ include thyroxine-binding protein, transthyretin, al-acid glycoprotein, transferrin, fibrinogen and albumin, or a fragment of any thereof.

As used herein, a ‘circulating immunoglobulin molecule’ includes IgG1, IgG2, IgG3, IgG4, sIgA, IgM and IgD, or a fragment of any thereof.

CD35/CR1 is a protein present on red blood cells which have a half-life of 36 days (normal range of 28 to 47 days; Lanaro et al., 1971, Cancer, 28(3):658-661).

In one embodiment, the protein for which V₁/V₂ has specificity is a serum carrier protein, such as a human serum carrier. In a most preferred embodiment, the serum carrier protein is human serum albumin.

Albumin binding variable regions and CDRs are disclosed in constructs shown in FIG. 1.

Thus in one embodiment there is provided a bi-specific antibody molecule comprising or consisting of three polypeptides;

a) a heavy chain of formula (Ia): VH-CH₁—X—V₁; and b) a light chain of formula (IIa): VL-C_(L) c) a polypeptide of formula (III): V₂ wherein V_(H) represents a heavy chain variable domain, CH₁ represents domain 1 of a heavy chain constant region, X represents a linker, V₁ represents a variable domain, V_(L) represents a light chain variable domain, C_(L) represents a constant region from a light chain, V₂ represents a variable region, wherein V_(H) and V_(L) are a cognate pair of variable regions aligned to form a binding domain and V₁ and V₂ are a cognate pair of variable regions aligned to form a binding domain optionally a disulphide bond there-between, for example wherein V₁ and V₂ are capable of binding albumin in vivo, in particular human serum albumin.

In one embodiment V1 or V2 comprise a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:83 and SEQ ID NO:86. In one embodiment V1 has the sequence given in SEQ ID NO:4 and V2 has the sequence given in SEQ ID NO:8. In one embodiment V1 has the sequence given in SEQ ID NO:86 and V2 has the sequence given in SEQ ID NO:83.

In one example V1 or V2, in particular V1, is a VH domain comprising the sequence given in SEQ ID NO:87 for CDRH-1, the sequence given in SEQ ID NO:88 for CDRH2 and the sequence given in SEQ ID NO:89 for CDRH-3. In one example V1 or V2, in particular V1, is a VH domain comprising the sequence given in SEQ ID NO:93 for CDRH-1, the sequence given in SEQ ID NO:94 for CDRH2 and the sequence given in SEQ ID NO:95 for CDRH-3.

In one embodiment V1 or V2, in particular V2, is a VL domain comprising the sequence given in SEQ ID NO:90 for CDRL-1, the sequence given in SEQ ID NO:91 for CDRL2 and the sequence given in SEQ ID NO:92 for CDRL-3. In one embodiment V1 or V2, in particular V2, is a VL domain comprising the sequence given in SEQ ID NO:96 for CDRL-1, the sequence given in SEQ ID NO:97 for CDRL2 and the sequence given in SEQ ID NO:98 for CDRL-3.

In one example V1 or V2, in particular V1, is a VH domain comprising the sequence given in SEQ ID NO:4, SEQ ID NO: 86, SEQ NO:99 or SEQ ID NO: 100.

In one example V1 or V2, in particular V2, is a VL domain comprising the sequence given in SEQ ID NO: 8, SEQ ID NO: 83, SEQ NO: 101 or SEQ ID NO: 102.

In one example V1 is a VH domain comprising the sequence given in SEQ NO:99 and V2 is a VL domain comprising the sequence given in SEQ NO:101.

In one example V1 is a VH domain comprising the sequence given in SEQ NO: 100 and V2 is a VL domain comprising the sequence given in SEQ NO: 102.

In one example polypeptide Ia has the sequence given in SEQ ID NO:6.

In one example polypeptide IIa has the sequence given in SEQ ID NO:7.

In one example polypeptide Ib has the sequence given in SEQ ID NO:3.

In one example polypeptide IIb has the sequence given in SEQ ID NO:5.

In one example polypeptide Ia has the sequence given in SEQ ID NO:6, polypeptide IIa has the sequence given in SEQ ID NO:7 and V₂ has the sequence given in SEQ ID NO:8.

In one example polypeptide Ib has the sequence given in SEQ ID NO:3, polypeptide IIb has the sequence given in SEQ ID NO:5 and V₁ has the sequence given in SEQ ID NO:4.

The invention also provides sequences which are 80%, 90%, 91%, 92%, 93% 94%, 95% 96%, 97%, 98% or 99% similar to a sequence or antibody disclosed herein.

“Identity”, as used herein, indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. “Similarity”, as used herein, indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be substituted for isoleucine or valine. Other amino acids which can often be substituted for one another include but are not limited to:

-   -   phenylalanine, tyrosine and tryptophan (amino acids having         aromatic side chains);     -   lysine, arginine and histidine (amino acids having basic side         chains);     -   aspartate and glutamate (amino acids having acidic side chains);     -   asparagine and glutamine (amino acids having amide side chains);         and     -   cysteine and methionine (amino acids having sulphur-containing         side chains). Degrees of identity and similarity can be readily         calculated (Computational Molecular Biology, Lesk, A. M., ed.,         Oxford University Press, New York, 1988; Biocomputing.         Informatics and Genome Projects, Smith, D. W., ed., Academic         Press, New York, 1993; Computer Analysis of Sequence Data, Part         1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New         Jersey, 1994; Sequence Analysis in Molecular Biology, von         Heinje, G., Academic Press, 1987, Sequence Analysis Primer,         Gribskov, M. and Devereux, J., eds., M Stockton Press, New York,         1991, the BLAST™ software available from NCBI (Altschul, S. F.         et al., 1990, J. Mol. Biol. 215:403-410; Gish, W. &         States, D. J. 1993, Nature Genet. 3:266-272. Madden, T. L. et         al., 1996, Meth. Enzymol. 266:131-141; Altschul, S. F. et al.,         1997, Nucleic Acids Res. 25:3389-3402; Zhang, J. & Madden, T. L.         1997, Genome Res. 7:649-656,).

In an alternative aspect the present invention provides a Fab or Fab′ fragment linked to a disulphide stabilised scFv, wherein the disulphide stabilised scFv (dsscFv) is linked to the C-terminus of the heavy or the light chain of the Fab or Fab′ fragment directly or via a linker such as a linker described herein. Preferably the Fab-dsscFv fusion protein is bi-specific. In one example the dsscFv binds a serum carrier protein such as human serum albumin. In one example the dsscFv is linked to C-terminus of the heavy chain of the Fab or Fab′ fragment by the linker given in SEQ ID NO:78. In one example the dsscFv is linked to the C-terminus of the light chain of the Fab or Fab′ fragment by the linker given in SEQ ID NO: 103. In one example the heavy chain of the Fab-dsscFv has the sequence given in SEQ ID NO:9 and the light chain has the sequence given in SEQ ID NO: 10. In one example the heavy chain of the Fab-dsscFv has the sequence given in SEQ ID NO: 11 and the light chain has the sequence given in SEQ ID NO: 12.

In one embodiment the bi-specific antibody molecules of the present disclosure are processed to provide improved affinity for a target antigen or antigens. Such variants can be obtained by a number of affinity maturation protocols including mutating the CDRs (Yang et al., J. Mol. Biol., 254, 392-403, 1995), chain shuffling (Marks et al., Bio/Technology, 10, 779-783, 1992), use of mutator strains of E. coli (Low et al., J. Mol. Biol., 250, 359-368, 1996), DNA shuffling (Patten et al., Curr. Opin. Biotechnol., 8, 724-733, 1997), phage display (Thompson et al., J. Mol. Biol., 256, 77-88, 1996) and sexual PCR (Crameri et al., Nature, 391, 288-291, 1998). Vaughan et al. (supra) discusses these methods of affinity maturation.

Improved affinity as employed herein in this context refers to an improvement over the starting molecule.

If desired an antibody for use in the present invention may be conjugated to one or more effector molecule(s). It will be appreciated that the effector molecule may comprise a single effector molecule or two or more such molecules so linked as to form a single moiety that can be attached to the antibodies of the present invention. Where it is desired to obtain an antibody fragment linked to an effector molecule, this may be prepared by standard chemical or recombinant DNA procedures in which the antibody fragment is linked either directly or via a coupling agent to the effector molecule. Techniques for conjugating such effector molecules to antibodies are well known in the art (see, Hellstrom et al., Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-53; Thorpe et al., 1982, Immunol. Rev., 62:119-58 and Dubowchik et al., 1999, Pharmacology and Therapeutics, 83, 67-123). Particular chemical procedures include, for example, those described in WO 93/06231, WO 92/22583, WO 89/00195, WO 89/01476 and WO03031581. Alternatively, where the effector molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in WO 86/01533 and EP0392745.

The term effector molecule as used herein includes, for example, biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g. DNA, RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

Other effector molecules may include chelated radionuclides such as 111In and 90Y, Lu177, Bismuth213, Californium252, Iridium 192 and Tungsten 188/Rhenium 188; or drugs such as but not limited to, alkylphosphocholines, topoisomerase I inhibitors, taxoids and suramin.

Other effector molecules include proteins, peptides and enzymes. Enzymes of interest include, but are not limited to, proteolytic enzymes, hydrolases, lyases, isomerases, transferases. Proteins, polypeptides and peptides of interest include, but are not limited to, immunoglobulins, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin, a protein such as insulin, tumour necrosis factor, α-interferon, β-interferon, nerve growth factor, platelet derived growth factor or tissue plasminogen activator, a thrombotic agent or an anti-angiogenic agent, e.g. angiostatin or endostatin, or, a biological response modifier such as a lymphokine, interleukin-1 (IL-1), interleukin-2 (IL-2), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), nerve growth factor (NGF) or other growth factor and immunoglobulins.

Other effector molecules may include detectable substances useful for example in diagnosis. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive nuclides, positron emitting metals (for use in positron emission tomography), and nonradioactive paramagnetic metal ions. See generally U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radioactive nuclides include 125I, 13II, 11IIn and 99Tc.

In another example the effector molecule may increase the half-life of the antibody in vivo, and/or reduce immunogenicity of the antibody and/or enhance the delivery of an antibody across an epithelial barrier to the immune system. Examples of suitable effector molecules of this type include polymers, albumin, albumin binding proteins or albumin binding compounds such as those described in WO05/117984.

Where the effector molecule is a polymer it may, in general, be a synthetic or a naturally occurring polymer, for example an optionally substituted straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, e.g. a homo- or hetero-polysaccharide.

Specific optional substituents which may be present on the above-mentioned synthetic polymers include one or more hydroxy, methyl or methoxy groups.

Specific examples of synthetic polymers include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol) poly(vinylalcohol) or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol) or derivatives thereof. Specific naturally occurring polymers include lactose, amylose, dextran, glycogen or derivatives thereof. “Derivatives” as used herein is intended to include reactive derivatives, for example thiol-selective reactive groups such as maleimides and the like. The reactive group may be linked directly or through a linker segment to the polymer. It will be appreciated that the residue of such a group will in some instances form part of the product as the linking group between the antibody fragment and the polymer.

The size of the polymer may be varied as desired, but will generally be in an average molecular weight range from 500 Da to 50000 Da, for example from 5000 to 40000 Da such as from 20000 to 40000 Da. The polymer size may in particular be selected on the basis of the intended use of the product for example ability to localize to certain tissues such as tumors or extend circulating half-life (for review see Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). Thus, for example, where the product is intended to leave the circulation and penetrate tissue, for example for use in the treatment of a tumour, it may be advantageous to use a small molecular weight polymer, for example with a molecular weight of around 5000 Da. For applications where the product remains in the circulation, it may be advantageous to use a higher molecular weight polymer, for example having a molecular weight in the range from 20000 Da to 40000 Da.

Suitable polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 15000 Da to about 40000 Da.

In one example antibodies for use in the present invention are attached to poly(ethyleneglycol) (PEG) moieties. In one particular example the antibody is an antibody fragment and the PEG molecules may be attached through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using recombinant DNA methods (see for example U.S. Pat. Nos. 5,219,996; 5,667,425; WO98/25971, WO2008/038024). In one example the antibody molecule of the present invention is a modified Fab fragment wherein the modification is the addition to the C-terminal end of its heavy chain one or more amino acids to allow the attachment of an effector molecule. Suitably, the additional amino acids form a modified hinge region containing one or more cysteine residues to which the effector molecule may be attached. Multiple sites can be used to attach two or more PEG molecules.

Suitably PEG molecules are covalently linked through a thiol group of at least one cysteine residue located in the antibody fragment. Each polymer molecule attached to the modified antibody fragment may be covalently linked to the sulphur atom of a cysteine residue located in the fragment. The covalent linkage will generally be a disulphide bond or, in particular, a sulphur-carbon bond. Where a thiol group is used as the point of attachment appropriately activated effector molecules, for example thiol selective derivatives such as maleimides and cysteine derivatives may be used. An activated polymer may be used as the starting material in the preparation of polymer-modified antibody fragments as described above. The activated polymer may be any polymer containing a thiol reactive group such as an α-halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone or a disulphide. Such starting materials may be obtained commercially (for example from Nektar, formerly Shearwater Polymers Inc., Huntsville, Ala., USA) or may be prepared from commercially available starting materials using conventional chemical procedures. Particular PEG molecules include 20K methoxy-PEG-amine (obtainable from Nektar, formerly Shearwater; Rapp Polymere; and SunBio) and M-PEG-SPA (obtainable from Nektar, formerly Shearwater).

In one embodiment, a Fab or Fab′ in the molecule is PEGylated, i.e. has PEG (poly(ethyleneglycol)) covalently attached thereto, e.g. according to the method disclosed in EP 0948544 or EP1090037 [see also “Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications”, 1992, J. Milton Harris (ed), Plenum Press, New York, “Poly(ethyleneglycol) Chemistry and Biological Applications”, 1997, J. Milton Harris and S. Zalipsky (eds), American Chemical Society, Washington D.C. and “Bioconjugation Protein Coupling Techniques for the Biomedical Sciences”, 1998, M. Aslam and A. Dent, Grove Publishers, New York; Chapman, A. 2002, Advanced Drug Delivery Reviews 2002, 54:531-545]. In one example PEG is attached to a cysteine in the hinge region. In one example, a PEG modified Fab fragment has a maleimide group covalently linked to a single thiol group in a modified hinge region. A lysine residue may be covalently linked to the maleimide group and to each of the amine groups on the lysine residue may be attached a methoxypoly(ethyleneglycol) polymer having a molecular weight of approximately 20,000 Da. The total molecular weight of the PEG attached to the Fab fragment may therefore be approximately 40,000 Da.

Particular PEG molecules include 2-[3-(N-maleimido)propionamido]ethyl amide of N,N′-bis(methoxypoly(ethylene glycol) MW 20,000) modified lysine, also known as PEG2MAL40K (obtainable from Nektar, formerly Shearwater).

Alternative sources of PEG linkers include NOF who supply GL2-400MA2 (wherein m in the structure below is 5) and GL2-400MA (where m is 2) and n is approximately 450:

-   -   m is 2 or 6         That is to say each PEG is about 20,000 Da.         Further alternative PEG effector molecules of the following         type:

are available from Dr Reddy, NOF and Jenkem.

In one embodiment there is provided an antibody which is PEGylated (for example with a PEG described herein), attached through a cysteine amino acid residue at or about amino acid 226 in the chain, for example amino acid 226 of the heavy chain (by sequential numbering).

In one embodiment there is provided a polynucleotide sequence encoding a molecule of the present disclosure, such as a DNA sequence.

In one embodiment there is provided a polynucleotide sequence encoding one or more, such as two or more polypeptide components of a molecule of the present disclosure, for example

a polypeptide chain of formula (I): (Vxx)_(n)Vx-Cx-X-V₁ a polypeptide chain of formula (II): (Vyy)_(n)Vy-C_(y) or a polypeptide of formula (III): V₂ wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region domain, X represents a linker, V₁ represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region domain, V₂ represents a variable domain,

-   -   n independently represents 0 or 1.

In one embodiment the polynucleotide, such as the DNA is comprised in a vector.

General methods by which the vectors may be constructed, transfection methods and culture methods are well known to those skilled in the art. In this respect, reference is made to “Current Protocols in Molecular Biology”, 1999, F. M. Ausubel (ed), Wiley Interscience, New York and the Maniatis Manual produced by Cold Spring Harbor Publishing.

Also provided is a host cell comprising one or more cloning or expression vectors comprising one or more DNA sequences encoding an antibody of the present invention. Any suitable host cell/vector system may be used for expression of the DNA sequences encoding the antibody molecule of the present invention. Bacterial, for example E. coli, and other microbial systems may be used or eukaryotic, for example mammalian, host cell expression systems may also be used. Suitable mammalian host cells include CHO, myeloma or hybridoma cells.

The present invention also provides a process for the production of an antibody molecule according to the present invention comprising culturing a host cell containing a vector of the present invention under conditions suitable for leading to expression of protein from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.

For production of products comprising both heavy and light chains, the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides. In one example the cell line may be transfected with three vectors, each encoding a polypeptide chain of an antibody molecule of the present invention. In one example the cell line is transfected with three vectors each one encoding a different polypeptide selected from a) a polypeptide chain of formula (I): (Vxx)_(n)Vx-Cx-X-V₁; b) a polypeptide chain of formula (II): (Vyy)_(n)Vy-C_(y) and c) a polypeptide of formula (III): V₂ wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region domain, X represents a linker, V₁ represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region domain, V₂ represents a variable domain, n independently represents 0 or 1,

It will be appreciated that the ratio of each vector transfected into the host cell may be varied in order to optimise expression of the multi-specific antibody product. In one embodiment the ratio of vectors is 1:1:1. It will be appreciated that skilled person is able to find an optimal ratio by routine testing of protein expression levels following transfection.

It will also be appreciated that where two or more, in particular three of more, of the polypeptide components are encoded by a polynucleotide in a single vector the relative expression of each polypeptide component can be varied by utilising different promoters for each polynucleotide encoding a polypeptide component of the present invention.

In one embodiment the vector comprises a single polynucleotide sequence encoding all three polypeptide chains of the multispecific antibody molecule of the present invention under the control of a single promoter.

In one embodiment the vector comprises a single polynucleotide sequence encoding all three polypeptide chains of the multispecific antibody molecule of the present invention wherein each polynucleotide sequence encoding each polypeptide chain is under the control of a different promoter.

The antibodies and fragments according to the present disclosure are expressed at good levels from host cells. Thus the properties of the antibodies and/or fragments appear to be optimised and conducive to commercial processing.

The antibodies of the present invention are useful in the treatment and/or prophylaxis of a pathological condition.

The present invention also provides a pharmaceutical or diagnostic composition comprising an antibody molecule of the present invention in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. Accordingly, provided is the use of an antibody of the invention for use in treatment and for the manufacture of a medicament.

The composition will usually be supplied as part of a sterile, pharmaceutical composition that will normally include a pharmaceutically acceptable carrier. A pharmaceutical composition of the present invention may additionally comprise a pharmaceutically-acceptable adjuvant.

The present invention also provides a process for preparation of a pharmaceutical or diagnostic composition comprising adding and mixing the antibody molecule of the present invention together with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

The antibody molecule may be the sole active ingredient in the pharmaceutical or diagnostic composition or may be accompanied by other active ingredients including other antibody ingredients, for example anti-TNF, anti-IL-1β, anti-T cell, anti-IFNγ or anti-LPS antibodies, or non-antibody ingredients such as xanthines. Other suitable active ingredients include antibodies capable of inducing tolerance, for example, anti-CD3 or anti-CD4 antibodies.

In a further embodiment the antibody, fragment or composition according to the disclosure is employed in combination with a further pharmaceutically active agent, for example a corticosteroid (such as fluticasonoe propionate) and/or a beta-2-agonist (such as salbutamol, salmeterol or formoterol) or inhibitors of cell growth and proliferation (such as rapamycin, cyclophosphmide, methotrexate) or alternatively a CD28 and/or CD40 inhibitor. In one embodiment the inhibitor is a small molecule. In another embodiment the inhibitor is an antibody specific to the target.

The pharmaceutical compositions suitably comprise a therapeutically effective amount of the antibody of the invention. The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any antibody, the therapeutically effective amount can be estimated initially either in cell culture assays or in animal models, usually in rodents, rabbits, dogs, pigs or primates. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

The precise therapeutically effective amount for a human subject will depend upon the severity of the disease state, the general health of the subject, the age, weight and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, a therapeutically effective amount will be from 0.01 mg/kg to 50 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Alternatively, the dose may be 1 to 500 mg per day such as 10 to 100, 200, 300 or 400 mg per day. Pharmaceutical compositions may be conveniently presented in unit dose forms containing a predetermined amount of an active agent of the invention.

Compositions may be administered individually to a patient or may be administered in combination (e.g. simultaneously, sequentially or separately) with other agents, drugs or hormones.

The dose at which the antibody molecule of the present invention is administered depends on the nature of the condition to be treated, the extent of the inflammation present and on whether the antibody molecule is being used prophylactically or to treat an existing condition.

The frequency of dose will depend on the half-life of the antibody molecule and the duration of its effect. If the antibody molecule has a short half-life (e.g. 2 to 10 hours) it may be necessary to give one or more doses per day. Alternatively, if the antibody molecule has a long half-life (e.g. 2 to 15 days) it may only be necessary to give a dosage once per day, once per week or even once every 1 or 2 months.

The pharmaceutically acceptable carrier should not itself induce the production of antibodies harmful to the individual receiving the composition and should not be toxic. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used, for example mineral acid salts, such as hydrochlorides, hydrobromides, phosphates and sulphates, or salts of organic acids, such as acetates, propionates, malonates and benzoates.

Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents or pH buffering substances, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions, for ingestion by the patient.

Suitable forms for administration include forms suitable for parenteral administration, e.g. by injection or infusion, for example by bolus injection or continuous infusion. Where the product is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents, such as suspending, preservative, stabilising and/or dispersing agents. Alternatively, the antibody molecule may be in dry form, for reconstitution before use with an appropriate sterile liquid.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals. However, in one or more embodiments the compositions are adapted for administration to human subjects.

In one embodiment, in formulations according to the present disclosure, the pH of the final formulation is not similar to the value of the isoelectric point of the antibody or fragment, for if the pH of the formulation is 7 then a pI of from 8-9 or above may be appropriate. Whilst not wishing to be bound by theory it is thought that this may ultimately provide a final formulation with improved stability, for example the antibody or fragment remains in solution.

The pharmaceutical compositions of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, transcutaneous (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal routes. Hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. Preferably the antibody molecules of the present invention are administered subcutaneously, by inhalation or topically.

Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a specific tissue of interest. Dosage treatment may be a single dose schedule or a multiple dose schedule.

It will be appreciated that the active ingredient in the composition will be an antibody molecule. As such, it will be susceptible to degradation in the gastrointestinal tract. Thus, if the composition is to be administered by a route using the gastrointestinal tract, the composition will need to contain agents which protect the antibody from degradation but which release the antibody once it has been absorbed from the gastrointestinal tract.

A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Publishing Company, N.J. 1991).

In one embodiment the formulation is provided as a formulation for topical administrations including inhalation.

Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases (such as nebulisable solutions or suspensions). Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the above mentioned active substances with physiologically acceptable excipient.

These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another. Mono- or disaccharides are suitably used, the use of lactose or glucose, particularly but not exclusively in the form of their hydrates.

Particles for deposition in the lung require a particle size less than 10 microns, such as 1-9 microns for example from 0.1 to 5 μm, in particular from 1 to 5 μm. The particle size of the active (such as the antibody or fragment is of primary importance).

The propellent gases which can be used to prepare the inhalable aerosols are known in the art. Suitable propellent gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The abovementioned propellent gases may be used on their own or in mixtures thereof.

Particularly suitable propellent gases are halogenated alkane derivatives selected from among TG 11, TG 12, TG 134a and TG227. Of the abovementioned halogenated hydrocarbons, TG134a (1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof are particularly suitable.

The propellent-gas-containing inhalable aerosols may also contain other ingredients such as cosolvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.

The propellant-gas-containing inhalable aerosols according to the invention may contain up to 5% by weight of active substance. Aerosols according to the invention contain, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1% by weight of active.

Alternatively topical administrations to the lung may also be by administration of a liquid solution or suspension formulation, for example employing a device such as a nebulizer, for example, a nebulizer connected to a compressor (e.g., the Pad LC-Jet Plus® nebulizer connected to a Pari Master® compressor manufactured by Pari Respiratory Equipment, Inc., Richmond, Va.).

In one embodiment the formulation is provided as discrete ampoules containing a unit dose for delivery by nebulisation.

In one embodiment the antibody is supplied in lyophilised form, for reconstitutions or alternatively as a suspension formulation.

The antibody of the invention can be delivered dispersed in a solvent, e.g., in the form of a solution or a suspension. It can be suspended in an appropriate physiological solution, e.g., physiological saline, a pharmacologically acceptable solvent or a buffered solution. Buffered solutions known in the art may contain 0.05 mg to 0.15 mg disodium edetate, 8.0 mg to 9.0 mg NaCl, 0.15 mg to 0.25 mg polysorbate, 0.25 mg to 0.30 mg anhydrous citric acid, and 0.45 mg to 0.55 mg sodium citrate per 1 ml of water so as to achieve a pH of about 4.0 to 5.0. As mentioned supra a suspension can made, for example, from lyophilised antibody.

The therapeutic suspensions or solution formulations can also contain one or more excipients.

Excipients are well known in the art and include buffers (e.g., citrate buffer, phosphate buffer, acetate buffer and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. Solutions or suspensions can be encapsulated in liposomes or biodegradable microspheres. The formulation will generally be provided in a substantially sterile form employing sterile manufacture processes.

This may include production and sterilization by filtration of the buffered solvent solution used for the formulation, aseptic suspension of the antibody in the sterile buffered solvent solution, and dispensing of the formulation into sterile receptacles by methods familiar to those of ordinary skill in the art.

Nebulisable formulation according to the present disclosure may be provided, for example, as single dose units (e.g., sealed plastic containers or vials) packed in foil envelopes. Each vial contains a unit dose in a volume, e.g., 2 ml, of solvent/solution buffer.

The antibodies of the present disclosure are thought to be suitable for delivery via nebulisation. It is also envisaged that the antibody of the present invention may be administered by use of gene therapy. In order to achieve this, DNA sequences encoding the heavy and light chains of the antibody molecule under the control of appropriate DNA components are introduced into a patient such that the antibody chains are expressed from the DNA sequences and assembled in situ.

The pathological condition or disorder, may, for example be selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis such as rheumatoid arthritis, asthma such as severe asthma, chronic obstructive pulmonary disease (COPD), pelvic inflammatory disease, Alzheimer's Disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme disease, meningoencephalitis, autoimmune uveitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis, lupus (such as systemic lupus erythematosus) and Guillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis, fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathic thrombocytopenic purpura, Meniere's disease, pemphigus, primary biliary cirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, osteoarthritis, periodontitis and hypochlorhydia.

The present invention also provides an antibody molecule according to the present invention for use in the treatment or prophylaxis of pain, particularly pain associated with inflammation.

Thus there is provided an antibody according to the invention for use in treatment and methods of treatment employing same.

In one embodiment there is provided a process for purifiying an antibody (in particular an antibody or fragment according to the invention).

In one embodiment there is provided a process for purifiying an antibody (in particular an antibody or fragment according to the invention) comprising the steps: performing anion exchange chromatography in non-binding mode such that the impurities are retained on the column and the antibody is maintained in the unbound fraction. The step may, for example be performed at a pH about 6-8.

The process may further comprise an initial capture step employing cation exchange chromatography, performed for example at a pH of about 4 to 5.

The process may further comprise of additional chromatography step(s) to ensure product and process related impurities are appropriately resolved from the product stream.

The purification process may also comprise of one or more ultra-filtration steps, such as a concentration and diafiltration step.

Purified form as used supra is intended to refer to at least 90% purity, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% w/w or more pure.

Substantially free of endotoxin is generally intended to refer to an endotoxin content of 1 EU per mg antibody product or less such as 0.5 or 0.1 EU per mg product.

Substantially free of host cell protein or DNA is generally intended to refer to host cell protein and/or DNA content 400 μg per mg of antibody product or less such as 100 μg per mg or less, in particular 20 μg per mg, as appropriate.

The antibody molecule of the present invention may also be used in diagnosis, for example in the in vivo diagnosis and imaging of disease states involving OX40.

Comprising in the context of the present specification is intended to meaning including.

Where technically appropriate embodiments of the invention may be combined.

Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.

The present invention is further described by way of illustration only in the following examples, which refer to the accompanying Figures, in which:

EXAMPLES Example 1: Single Linker Fab-dsFv

Construction of Single Linker A26Fab-645dsFv, A26Fab-645dsFv and A26Fab-645dsscFv Plasmids for Expression in Mammalian Cells

A26Fab fusion proteins for the expression of single linker A26Fab-645dsFv and A26Fab-645dsFv, see FIG. 1, were constructed by fusing 645vL to the C-terminus of the Km3 allotype human kappa constant region of the A26 light chain using the flexible linker SGGGGSGGGGSGGGGS (SEQ ID NO: 103), or by fusing 645vH to the C-terminus of the, γ1 isotype human gamma-1 CH1 constant region of the A26 heavy chain using the flexible linker SGGGGSGGGGTGGGGS (SEQ ID NO: 78). In addition point mutations were introduced into the DNA sequences at selected residues in the framework region of both 645vL and 645vH. The mutations (heavy chain G44C and light chain G100C) were introduced to create an interchain disulphide bond between the heavy and light chains of the 645Fv. A26Fab fusion proteins for the expression of A26Fab-645dsscFv, see FIG. 1, were constructed as follows. A single chain Fv (scFv) was constructed by linking the N-terminus of 645vL to the C-terminus of 645vH via the flexible linker GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 79). Point mutations were introduced into the DNA sequence at framework residues G100C in 645vL and G44C in 645vH to make the disulphide linked scFv (dsscFv). The 645dsscFv was then fused to the C-terminus of either the Km3 allotype human kappa constant region of the A26 light chain using the flexible linker SGGGGSGGGGS (SEQ ID NO: 104), or to the yl isotype human gamma-1 CH1 constant region of the A26 heavy chain using the flexible linker SGGGGTGGGGS (SEQ ID NO: 80). The A26Fab light chain-645dsvL, A26Fab heavy chain-645dsvH, A26Fab light chain, A26Fab heavy chain, 645dsvL free domain, 645dsvH free domain, A26Fab light chain-645dsscFv and A26Fab heavy chain-645dsscFv were manufactured chemically and individually cloned into mammalian expression vectors under the control of the HCMV-MIE promoter and SV40E polyA sequence.

HEK293 expression of single linker A26Fab-645dsFv, A26Fab-645dsFv and A26Fab-645dsscFv

HEK293 cells were transfected with the relevant plasmids using Invitrogen's 293fectin™ transfection reagent according to the manufacturer's instructions. Plasmids were mixed as follows to express the different constructs; for A26Fab-645dsFv, the plasmids were A26Fab Heavy-(S, 3xG4S/T)-645dsvH and A26Fab Light-(S, 3xG4S)-645dsvL; for Single linker A26Fab-645dsFv (LC-vL linked), the plasmids were A26Fab Heavy, 645dsvH and A26Fab Light-(S, 3xG4S)-645dsvL; for Single linker A26Fab-645dsFv (HC-vH linked), the plasmids were A26Fab Heavy-(S, 3xG4S/T)-645dsvH, A26Fab Light and 645dsvL; for A26Fab-645dsscFv (HC-scFv), the plasmids were A26Fab Heavy-(S, 2xG4S/T)-645dsscFv(vH-4xG4S-vL) and A26Fab Light; and for A26Fab-645dsscFv (LC-scFv), the plasmids were A26Fab Heavy and A26Fab Light-(S, 2xG4S)-645dsscFv(vH-4xG4S-vL). In addition the ratio of the plasmids used for the transfections also varied, for the 2 plasmid combinations the ratio was 1:1, whereas for the 3 plasmid combinations several different ratios were tested. A total of 50 μg of plasmid DNA was incubated with 125 μl 1 293fectin+4.25 ml Optimem™ media for 20 mins at RT. The mixture was then added to 50 ml of HEK293 cells in suspension at 1×10⁶ cells/ml and incubated with shaking at 37° C. Supernatants were harvested on day 7 by centrifugation at 1500 g to remove cells and the supernatant passed through a 0.22 μm filter. Expression level was determined by Protein-G HPLC.

The level of expression of all the constructs was comparable, see table 4, covering the range 3-15 g/ml. The Fab-dsFv expressed at 13-14 μg/ml, the Fab-dsscFv's expressed at 7-15 g/ml and the single linker Fab-dsFv's expressed at 3-13 μg/ml. There have been reports in the literature that the expression of Fv regions that lack either a linker between the vL and vH or a dimerisation motif to bring the vL and vH together have substantially lower expression levels than linked Fv's. This is not observed in this data where there is no significant difference observed between the best expression of each type of construct.

TABLE 4 Expression level Construct (μg/ml) A26Fab-645dsFv 13.2-14.2 A26Fab-645dsscFv (LC-scFv) 14.0-15.2 A26Fab-645dsscFv (HC-scFv) 6.6-7.1 single linker A26Fab-645dsFv (LC-vL linked)(ratio 1:1:1 LC-vL:HC:vH) 5.1-6.9 single linker A26Fab-645dsFv (LC-vL linked) (ratio 1:1:2 LC-vL:HC:vH) 3.3-3.5 single linker A26Fab-645dsFv (LC-vL linked) (ratio 2:1:2 LC-vL:HC:vH) 4.2-4.4 single linker A26Fab-645dsFv (LC-vL linked) (ratio 1:2:2 LC-vL:HC:vH) 4.2-4.3 single linker A26Fab-645dsFv (HC-vH linked) (ratio 1:1:1 HC-vH:LC:vL)  6.8-12.6 single linker A26Fab-645dsFv (HC-vH linked) (ratio 1:1:2 HC-vH:LC:vL) 7.8-8.1 single linker A26Fab-645dsFv (HC-vH linked) (ratio 2:1:2 HC-vH:LC:vL) 7.6-8.2 BIAcore™ analysis of HEK293 expressed simile linker A26Fab-645dsFv, A26Fab-645dsFv and A26Fab-645dsscFv

Binding affinities and kinetic parameters for the interactions of Fab-dsFv, Fab-dsscFv and single linker Fab-dsFv constructs were determined by surface plasmon resonance (SPR) conducted on a BIAcore™ T100 using CM5 sensor chips and HBS-EP (10 mM HEPES (pH7.4), 150 mM NaCl, 3 mM EDTA, 0.05% v/v surfactant P20) running buffer. Single linker Fab-dsFv samples were captured to the sensor chip surface using either a human F(ab′)₂-specific goat Fab (Jackson ImmunoResearch, 109-006-097) or an in-house generated anti human CH1 monoclonal antibody. Covalent immobilisation of the capture antibody was achieved by standard amine coupling chemistry.

Each assay cycle consisted of firstly capturing the Fab-dsFv, Fab-dsscFv or single linker Fab-dsFv construct using a 1 min injection, before an association phase consisting of a 3 min injection of antigen, after which dissociation was monitored for 5 min. After each cycle, the capture surface was regenerated with 2×1 min injections of 40 mM HCl followed by 30 s of 5 mM NaOH. The flow rates used were 10 μl/min for capture, 30 l/min for association and dissociation phases, and 10 l/min for regeneration.

For kinetic assays, either a titration of human serum albumin 50-6.25 nM, or a single concentration of OX40 of 25 nM was performed. A blank flow-cell was used for reference subtraction and buffer-blank injections were included to subtract instrument noise and drift.

Kinetic parameters were determined by simultaneous global-fitting of the resulting sensorgrams to a standard 1:1 binding model using BIAcoreIM T100 Evaluation software.

The on rates, off rates and affinities of all the samples are similar for both antigens, human serum albumin (HSA) and human OX40, see table 5. Therefore the presence and position of the different linkers in the different constructs does not have a significant effect on the affinity of either variable region for its antigen.

TABLE 5 Sample Antigen ka (1/Ms) kd (1/s) KD (nM) Antigen ka (1/Ms) kd (1/s) KD (pM) A26Fab-645dsFv HSA 7.51E+04 1.51E−04 2.01 OX40 1.70E+05 1.53E−05 90 (start) A26Fab-645dsscFv HSA 1.83E+05 2.40E−04 1.31 OX40 1.66E+05 2.34E−05 141 (HC-scFv) A26Fab-645dsscFv HSA 1.72E+05 2.22E−04 1.29 OX40 1.78E+05 1.82E−05 102 (LC-scFv) Single linker A26Fab-645dsFv (LC-vL) HSA 7.40E+04 2.35E−04 3.17 OX40 2.29E+05 2.64E−05 115 (ratio 1:1:1 LC-vL:HC:vH) Single linker A26Fab-645dsFv (LC-vL) HSA 1.13E+05 2.62E−04 2.31 OX40 1.84E+05 1.80E−05 98 (ratio 1:1:2 LC-vL:HC:vH) Single linker A26Fab-645dsFv (LC-vL) HSA 1.26E+05 1.88E−04 1.49 OX40 1.70E+05 1.69E−05 99 (ratio 2:1:2 LC-vL:HC:vH) Single linker A26Fab-645dsFv (LC-vL) HSA 9.10E+04 2.23E−04 2.46 OX40 1.54E+05 1.70E−05 110 (ratio 1:1:1 LC-vL:HC:vH) Single linker A26Fab-645dsFv (HC-vH) HSA 2.09E+05 2.09E−04 1.00 OX40 1.73E+05 3.51E−05 203 (Ratio 1:1:1 HC-vH:LC:vL) Single linker A26Fab-645dsFv (HC-vH) HSA 2.11E+05 2.34E−04 1.11 OX40 1.92E+05 1.00E−05 52 (Ratio 1:1:2 HC-vH:LC:vL) Single linker A26Fab-645dsFv (HC-vH) HSA 1.97E+05 2.07E−04 1.05 OX40 1.94E+05 1.97E−05 101 (Ratio 2:1:2 HC-vH:LC:vL) A26Fab-645dsFv HSA 6.82E+04 2.12E−04 3.11 OX40 1.93E+05 1.98E−05 102 (end) Protein-G purification of HEK293 expressed single linker A26Fab-645dsFv, A26Fab-645dsFv and A26Fab-645dsscFv

The ˜50 ml HEK293 supernatants were concentrated ˜25 fold to ˜2 ml using 10kDa molecular weight cut off centrifugation concentrators. The concentrated supernatants were applied to a 1 ml HiTrap® Protein-G FF column (GE Healthcare) equilibrated in 20 mM phosphate, 40 mM NaCl pH7.4. The column was washed with 20 mM phosphate, 40 mM NaCl pH7.4 and the bound material eluted with 0.1M glycine/HCl pH2.7. The elution peak was collected and pH adjusted to ˜pH7 with 2M Tris/HCl pH8.5. The pH adjusted elutions were concentrated and buffer exchanged into PBS pH7.4 using 10 kDa molecular weight cut off centrifugation concentrators.

SDS-PAGE Analysis of Protein-G Purified, HEK293 Expressed, Single Linker A26Fab-645dsFv, A26Fab-645dsFv and A26Fab-645dsscFv

Samples were diluted with water where required and then to 26 μl was added 10 μL 4×Bis-Tris LDS sample buffer and 4 μL of 10× reducing agent for reduced samples. The samples were vortex mixed, incubated at 100° C. for 3 minutes, cooled and centrifuged at 12500 rpm for 30 seconds. The prepared samples were loaded on to a 4-20% acrylamine Tris/Glycine SDS gel and run for 110 minutes at 125V, constant voltage. The gels were stained with Coomassie Blue protein stain, see FIG. 2.

The reducing SDS-PAGE gel has banding patterns in terms of both migration position and staining intensity that is constant with all the constructs being expressed correctly. For Fab-dsFv, lane 2, there should be 2 bands at ˜36 and ˜37 kDa with roughly equivalent staining. For Fab-dsscFv (LC-scFv), lane 3, there should be 2 bands at ˜51 and ˜23 kDa with roughly twice the staining in the upper band. For Fab-dsscFv (HC-scFv), lane 4, there should be 2 bands at ˜50 and ˜26 kDa with roughly twice the staining in the upper band. For single linker Fab-dsFv (LC-vL), lanes 6-9, there should be 3 bands at ˜36, ˜23 and ˜13 kDa with staining roughly in the ratio 3:2:1 upper to lower band. For single linker Fab-dsFv (HC-vH), lanes 10-12, there should be 3 bands at ˜37, ˜26 and ˜12 kDa with staining roughly in the ratio 3:2:1 upper to lower band.

G3000 SEC-HPLC analysis of Protein-G purified, HEK293 expressed, single linker A26Fab-645dsFv, A26Fab-645dsFv and A26Fab-645dsscFv

50 μg samples were injected onto a TSK gel® G3000SWXL, 7.8x300 mm, column (Tosoh) and developed with an isocratic gradient of 200 mM phosphate pH7.0 at 1 ml/min. Signal detection was by absorbance at 280 nm, see FIG. 3. After Protein-G purification A26Fab-645dsFv is ˜45% monomer, A26Fab-645dsscFv's have slightly more monomer in the range 55-60%, whereas the single linker A26Fab-645dsFv's are all in excess of 80% monomer with some being 100% monomer.

Example 2

Construction of single linker A26Fab-645dsFv and A26Fab-648dsFv triple gene plasmids for expression in mammalian cells

The triple gene plasmids were constructed by first generating an intermediate double gene vector from the single gene components of the single linker Fab-dsFv formats as described in example 1/FIG. 1. The gene fragment encoding the expression of the heavy chain which includes the hCMV-MIE promoter, the heavy chain and SV40 polyA region, was sub-cloned downstream of the light chain gene in a mammalian expression vector. The heavy chain is either a A26 Fab heavy chain or the A26 Fab heavy linked to a 645dsvH or 648dsvH via a linker (S, 3xG₄S), and the light chain is either a A26 Fab light linked to a 645dsvL or 648dsvL via a linker (S, 3xG₄S) or a A26 Fab light chain, respectively. This generated the intermediate double gene plasmid for each format. To construct the triple gene plasmid, the fragment encoding the expression of the free cognate v region (645dsvL, 648dsvL, 645dsvH or 648dsvH), was subsequently sub-cloned at a unique restriction site downstream of the heavy chain gene in the intermediate vector. For future stable cell line generation, a mammalian selection marker was finally sub-cloned into the expression plasmids. This provided a set of plasmids that contained the relevant genes for single linker Fab-dsFv expression at equal gene ratios, with or without a mammalian selection marker. These plasmids will be used for initial assessment in a transient mammalian expression system for comparison with % monomer (FIG. 3) of single linker Fab-dsFvs expressed from single gene plasmids.

Transient Expression of single linker A26Fab-645dsFv and A26Fab-648dsFv from triple gene plasmids in CHO cells

CHO cells were grown in CD CHO media supplemented with 1x L-glutaMAX™ (Life Technologies) to exponential phase with >99% viability. The cells were prepared by washing in Earle's balanced salt solution (Life Technologies) and plasmid DNA was electroporated into the CHO cells according to in-house recommendations. The transfected cells were transferred to CD CHO medium supplemented with 1x L-glutaMAX™ and 1x anti-mycotic solution (Life Technologies) and incubated in an orbital shaker for 24 h at 37° C., 8% CO₂, and shaking at 140 rpm. Following incubation, or when the cultures had reached a viable cell density of at least 2×10⁶ cells ml⁻¹, the temperature was decreased to 32° C. Subsequently after 72 h post-transfection, 3 mM sodium butyrate (Sigma Aldrich) was added and the cultures were re-incubated for a further 11 days at 32° C., with 8% CO₂ and shaking at 140 rpm. The supernatant was harvested by centrifugation and successively filtered through 0.45 μM and 0.22 μM sterile filters. Expression titres were quantified by protein G HPLC against a Fab fragment standard.

The level of expression from triple gene plasmids was dependent on the presence of the mammalian selection marker, see FIG. 5. Expression titres were higher amongst single linker A26 Fab-dsFv proteins expressed from plasmids without a mammalian selection marker whereas lower but comparable levels were obtained if expressed from plasmids with the mammalian selection marker, as would be expected due to the metabolic burden exacted by expression of an extra gene. Additionally, higher expression titres were observed for proteins that contained an A26 Fab light linked to a 645dsvL or 648dsvL chain.

Protein G purification of single linker A26Fab-645dsFv and A26Fab-648dsFv expressed from triple gene plasmids in CHO cells

The 200 ml supernatants were concentrated by ˜20-fold using a 10 kDa molecular weight cut off centrifugation concentrators. The concentrated supernatants were applied to a 1 ml HiTrap® Protein-G FF column (GE Healthcare) equilibrated in 20 mM phosphate, 40 mM NaCl pH7.4. The column was washed with 20 mM phosphate, 40 mM NaCl pH7.4 and the bound material eluted with 0.1M glycine/HCl pH2.7. The elution peak was collected and the pH adjusted to ˜pH7 with Tris/HCl pH8.5. The pH adjusted elutions were concentrated and buffer exchanged into PBS pH7.4 using 10 kDa molecular weight cut off centrifugation concentrators. Protein concentrations were estimated spectrophotometrically at

A₂₈₀.

SDS-PAGE analysis of Protein-G purified simile linker A26Fab-645dsFv and A26Fab-648dsFv expressed from triple gene plasmids in CHO cells

Protein samples were diluted in PBS where required. To 8.25 μl of the subsequent sample, 3.75 μl of 4x Bis-Tris LDS sample buffer (Life Technologies), 1.5 μl of 100 mM N-ethylmaleimide and 1.5 μl of 10X reducing agent were added for reduced samples. The samples were vortex mixed, incubated at 100° C. for 3 minutes, cooled and centrifuged at 13200 rpm for 30 seconds. The prepared samples were loaded on to a 4-20% acrylamide Tris/Glycine SDS gel (Life Technologies) and run in Tris-glycine buffer for ˜150 minutes at 125V, constant voltage. An SDS-PAGE protein standard, Seeblue™2 (Life Technologies) was used as the standard marker. The gels were stained with InstantBlue™ Coomassie blue protein stain (Expedeon) and destained with distilled water, see FIG. 6.

The reducing SDS-PAGE gel has banding patterns in terms of both migration position and staining intensity that is constant with all the constructs being expressed correctly. For all single linker Fab-dsFv there should be 3 bands at ˜36-37 (i), ˜24-26 (ii) and ˜12-13 kDa (iii), with staining should be roughly in the ratio of 3:2:1 upper to lower band.

G3000 SEC-HPLC of Protein-G purified single linker A26Fab-645dsFv and A26Fab-648dsFv expressed from triple gene plasmids in CHO cells

50 μl samples were injected into a TSK gel® G3000SWXL, 7.8x300 mm, column (Tosoh) and developed with an isocratic gradient of 200 mM phosphate pH7.0 at 1 ml/min. Signal detection was by absorbance at 280 nm, see FIG. 7. All single linker A26Fab-645dsFvs expressed from triple gene plasmids, irrespective of the presence of a mammalian selection marker or expression level, achieve in excess of 90% monomer, with the majority being 100% monomer. This data is in good agreement with the monomeric single linker A26Fab-dsFvs expressed from single gene plasmids, FIG. 3. This also indicates that an equal gene ratio of the relevant genes encoding the format, as present in a triple gene plasmid configuration is optimal for highly monomeric single linker Fab-dsFv expression. 

The invention claimed is:
 1. An antibody molecule consisting of three polypeptides, (a) a polypeptide chain of formula (I): (Vxx)_(n)Vx-Cx-X-V₁, (b) a polypeptide chain of formula (II): (Vyy)_(n)Vy-C_(y), and (c) a polypeptide of formula (III): V₂, wherein: Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region consisting of C_(L) or CH₁, X represents a linker, V₁ represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region consisting of C_(L) or CH₁, V₂ represents a variable domain, n represents 0 or 1; wherein only one of Cx or Cy is CH₁; wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired, the variable domains Vx and Vy are paired to form a binding domain, the variable domains V₁ and V₂ are paired to form a binding domain, and a disulphide bond is present between V₁ and V₂; wherein n is either 0 in the polypeptide chains of formula (I) and (II), or n is 1 in the polypeptide chains of formula (I) and (II) and the variable domains Vxx and Vyy are paired to form a binding domain; wherein the variable domain pair V₁/V₂ are linked by a disulfide bond between two engineered cysteine residues, one in V₁ and one in V₂; and wherein the position of the pair of engineered cysteine residues is selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH100b and VL49, VH98 and VL46, VH101 and VL46, VH105 and VL43, and VH106 and VL57.
 2. The antibody molecule of claim 1, wherein (a) in the polypeptide chain of formula (I), n is 0 and Vx is V_(L), (b) in the polypeptide chain of formula (II), n is 0 and Vy is V_(H), (c) V_(H) represents a heavy chain variable domain, and (d) V_(L) represents a light chain variable domain.
 3. The antibody molecule of claim 1, wherein Cx is C_(L), V₁ represents a light chain variable domain and V₂ represents a heavy chain variable domain.
 4. The antibody molecule of claim 1, wherein Cx is CH₁, V₁ represents a heavy chain variable domain and V₂ represents a light chain variable domain.
 5. The antibody molecule of claim 1, wherein the variable domain pair V₁/V₂ have specificity for a serum carrier protein.
 6. The antibody molecule of claim 5, wherein V₂ comprises the sequence of SEQ ID NO:87 for CDRH-1, the sequence of SEQ ID NO:88 for CDRH2 and the sequence of SEQ ID NO:89 for CDRH-3 and V₁ comprises the sequence of SEQ ID NO:90 for CDRL-1, the sequence of SEQ ID NO:91 for CDRL2 and the sequence of SEQ ID NO:92 for CDRL-3.
 7. The antibody molecule of claim 5, wherein V₂ comprises the sequence of SEQ ID NO:93 for CDRH-1, the sequence of SEQ ID NO:94 for CDRH2 and the sequence of SEQ ID NO:95 for CDRH-3 and V₁ comprises the sequence of SEQ ID NO:96 for CDRL-1, the sequence of SEQ ID NO:97 for CDRL2 and the sequence of SEQ ID NO:98 for CDRL-3.
 8. The antibody molecule of claim 1, wherein X comprises the sequence of SEQ ID NO:103.
 9. The antibody molecule of claim 1, wherein a natural disulfide bond is present between Cx and Cy.
 10. The antibody molecule of claim 1, wherein at least one binding domain of the antibody molecule is specific for an antigen that is an immunoglobulin, an interferon, a colony stimulating factor, a viral antigen, a member of the classical and alternative complement activation cascade, an FcγR, a complement pathway protein, an integrin, or an interleukin.
 11. The antibody molecule of claim 10, wherein the at least one binding domain is specific for IgE.
 12. The antibody molecule of claim 10, wherein the at least one binding domain is specific for an interferon that is interferon α, interferon β, or interferon γ.
 13. The antibody molecule of claim 10, wherein the at least one binding domain is specific for a colony stimulating factor that is G-CSF or GM-CSF.
 14. The antibody molecule of claim 10, wherein the at least one binding domain is specific for a viral antigen that is a respiratory syncytial virus or cytomegalovirus, influenza, EBV, HepA, B, or C antigen.
 15. The antibody molecule of claim 10, wherein the at least one binding domain is specific for a member of the classical and alternative complement activation cascade that is C2, C4, C3-convertase, C5, C6, C7, C8, or C9.
 16. The antibody molecule of claim 10, wherein the at least one binding domain is specific for an FcγR that is FcγRI, FcγRII, or FcγRIII.
 17. The antibody molecule of claim 10, wherein the at least one binding domain is specific for a complement pathway protein that is C1q or C3.
 18. The antibody molecule of claim 10, wherein the at least one binding domain is specific for an integrin that is β1 integrin, VLA-4, E-selectin, P selectin, or L-selectin.
 19. The antibody molecule of claim 10, wherein the at least one binding domain is specific for an interleukin that is IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16, IL-17, or IL-23.
 20. The antibody molecule of claim 1, wherein at least one binding domain of the antibody molecule is specific for an antigen independently selected from the group consisting of an integrin, ICOS, BCMP7, CDCP1, DPCR1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, nectin-like2, NKCC1, PTK7, RAIG1, TCAM1, SC6, BCMP101, BCMP84, BCMP11, DTD, carcinoembryonic antigen (CEA), human milk fat globulin, MHC Class I and MHC Class II antigens, VEGF, an interleukin, a viral antigen, an immunoglobulin, an interferon, tumour necrosis factor-α, tumor necrosis factor-β, a colony stimulating factor, a platelet derived growth factor, a bacterial antigen, a snake and spider venom and toxin, OX40, histamine, C1q, opsonin, a member of the classical and alternative complement activation cascades, a FcγR, a complement pathway protein, a CD (Cluster of Differentiation) marker protein, a serum carrier protein, a circulating immunoglobulin molecule, and CD35/CR1.
 21. The antibody molecule of claim 20, wherein the CD marker protein is independently selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CD69, CD134, CD137 and CD27L.
 22. The antibody molecule of claim 1, wherein C_(L) represents Ckappa or Clambda.
 23. A pharmaceutical composition, comprising the antibody molecule of claim 1 and at least one excipient.
 24. A set of three polynucleotides, each polynucleotide encoding a different polypeptide chain of the antibody molecule of claim
 7. 25. A vector, comprising the polynucleotides of claim
 24. 26. A host cell, comprising the polynucleotides of claim
 24. 27. A host cell, comprising three vectors, each vector comprising a polynucleotide encoding a different polypeptide chain of the antibody molecule of claim
 1. 28. A process, comprising expressing an antibody molecule from the host cell of claim
 26. 